Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials

Abstract Progression Free Survival Ratio (PFSratio), as defined as the ratio between PFS on investigational treatment (PFS2) and PFS on the last prior therapy (PFS1), is a popular endpoint in precision oncology (PO) studies. In this work, five methodologies for PFSratio-based trial analysis (count-b...

Descripción completa

Detalles Bibliográficos

Autores principales:	Federico Nichetti, Jennifer Hüllein, Pauline du Rusquec, Erin Pleasance, Li Chen, Andreas Mock, Peter Horak, Paolo Ambrosini, Simone Rota, Monica Niger, Luca Agnelli, Gabriele Tinè, Dominic Edelmann, Christophe Le Tourneau, Janessa Laskin, Giancarlo Pruneri, Chi Wang, Daniel Hübschmann, Filippo de Braud, Stefan Fröhling, Luigi Mariani
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Nature Portfolio 2025-12-01
Colección:	npj Precision Oncology
Acceso en línea:	https://doi.org/10.1038/s41698-025-01231-x
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!